Receive our newsletter – data, insights and analysis delivered to you
July 15, 2009

ADVTX Presents New Drug to Protect Against Nuclear Fall-Out

Advanced Therapeutics (ADVTX) has revealed its new drug Fibrinoplate-S for the reduction of bleeding after radiation exposure. The treatment, which has shown effectiveness in reducing the bleeding in animals exposed to extreme doses of radiation, can also be administered to large groups q

By cms admin

Advanced Therapeutics (ADVTX) has revealed its new drug Fibrinoplate-S for the reduction of bleeding after radiation exposure.

The treatment, which has shown effectiveness in reducing the bleeding in animals exposed to extreme doses of radiation, can also be administered to large groups quickly.

In preclinical trials, Fibrinoplate-S reduced bleeding within two hours after a bolus intravenous administration in test subjects, with less than 1% of the normal platelet count. Beneficial effects were shown to last for at least 24 hours.

ADVTX CEO Richard Yen said that acute radiation can severely damage the bone marrow but that this treatment could be a effective alternative to platelet transfusion.

“While existing medications can boost the production of red cells and white cells from the recovering bone marrow, there is no effective treatment for low concentrations of platelets except through platelet transfusion. Donor platelets, however, may not be available or adequately screened for pathogens during times of distress,” Yen said.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU